It was a rather horrid hump day for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares today, as investor pessimism once again took over the markets.

After spending the entire session in red territory, the ASX 200 ended up closing down a nasty 1.18%. That leaves the index at 8,843.6 points at this mid-week point.

Today’s unhappy performance from the Australian markets follows a similarly negative night up on Wall Street.

The Dow Jones Industrial Average Index (DJX: .DJI) closed down 0.59% after initially rising during morning trading.

In a rare coincidence, the tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) also finished up with a 0.59% loss.

But let’s return to the local markets now and dive a little deeper into how today’s pessimism filtered down into the various ASX sectors.

Winners and losers

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• Top brokers name 3 ASX shares to buy today
• UBS names 3 ASX 200 shares to buy right now
• Why Ampol, Meteoric Resources, Praemium, and Treasury Wine shares are storming higher
• Why this ASX 200 energy stock is back in focus today
• Qube Holdings wins ASX waiver for flexible scheme timetable and dividend

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are looking to supercharge your portfolio with some big returns, then it could be worth checking out the two ASX shares in this article.

That’s because the team at Morgans has named them as buys with potential upside of 30% or more.

Here’s what the broker is recommending to clients:

Elementos Ltd (ASX: ELT)

This tin-focused mineral exploration company has caught the eye of Morgans.

It highlights that tin prices have lifted strongly since its definitive feasibility study (DFS) for the Oropesa project.

And with electrification and supply constraints expected to support tin prices over the medium term, the broker is feeling positive about Elementos’ outlook.

It has put a buy rating and 51 cents price target on its shares. This implies potential upside of 34% for investors from current levels. It said:

Recent strong tin price growth is expected to continue with electrification, supply constraints in the current geopolitical situation, and enhanced Environmental, Social and Governance (ESG) focus in tin producing jurisdictions. Since delivery of the definitive feasibility study for Oropesa, Spain, in May 2025, (US$156M capex, producing 3,400tpy of tin in concentrate, projected cost US$15,000/t) ELT has advanced the regulatory and administrative approvals.

Since the DFS, the tin price has lifted from ˜US$30,000/t to ˜US$50,000/t. We now model US$35,000/t (previously US$30,000/t) for tin to generate a Valuation of A$0.57ps (previously A$0.50) and a Target Price discounted by 10% to A$0.51ps.

Regal Partners Ltd (ASX: RPL)

Another ASX share that Morgans is recommending to clients is fund manager Regal Partners.

Although it had a soft quarter and has trimmed its earnings estimates, the broker remains positive.

It has put a buy rating and $4.20 price target on Regal Partners’ shares. Based on its current share price of $2.45, this suggests that upside of 70% is possible between now and this time next year. It commented:

RPL has released its March 2026 quarterly FUM update. This was a soft quarter (FUM -3%) for RPL as hedge fund investment performance suffered on the back of volatile market conditions. FUM bounced back in Apr-26. We update our RPL numbers for the quarterly following a broad review of our FUM expectations for the CY26.

Our CY26/27/28F EPS estimates are revised down -2%, reflecting more conservative FUM assumptions for the current year. Our valuation declines on the back of lower peer multiples and higher cost of capital assumptions. Target price $4.20/sh. We maintain our RPL BUY rating with >20% upside to our price target.

The post Morgans says these ASX shares could rise 30% to 70% appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Where to invest $20,000 in ASX ETFs right now
• CSL’s collapse deepens. Why this ASX giant can’t find a floor
• Top brokers name 3 ASX shares to buy today
• Drones, defence, and demand: Why this ASX stock is running hot in 2026

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Putting $20,000 to work in the share market can feel daunting.

But don’t let that put you off, even if you don’t like picking stocks.

That’s because exchange traded funds (ETFs) offer an easy way to put the money to work in the share market. They provide diversification, access to long-term themes, and a clear structure without requiring constant management.

Here are three ASX ETFs to consider for the $20,000.

BetaShares Global Defence ETF (ASX: ARMR)

The first ASX ETF to consider is the BetaShares Global Defence ETF.

This ETF provides investors with exposure to companies involved in the global defence sector. It includes businesses linked to military equipment, cybersecurity, and defence technology, including our very own DroneShield Ltd (ASX: DRO).

Spending in this area has been increasing as governments respond to shifting geopolitical conditions. That trend has supported long-term demand for defence-related products and services.

For investors, the BetaShares Global Defence ETF offers a way to access this theme without needing to identify individual international companies.

This fund was recently recommended by analysts at Betashares.

Global X Battery Tech & Lithium ETF (ASX: ACDC)

Another ASX ETF to consider is the Global X Battery Tech & Lithium ETF.

This ETF is built around the global transition to electrification. It holds companies involved in lithium mining, battery production, and electric vehicle supply chains. This includes Tesla (NASDAQ: TSLA) and Pilbara Minerals Ltd (ASX: PLS).

Demand for battery technology continues to grow as industries move toward cleaner energy and transportation solutions. This creates a broad opportunity set across both resource producers and technology companies.

The Global X Battery Tech & Lithium ETF provides exposure to that ecosystem in a single investment. It allows investors to participate in the long-term shift without needing to pick individual winners in a rapidly evolving space. It was recently recommended by Global X.

VanEck Australian Equal Weight ETF (ASX: MVW)

A final ASX ETF to consider for the $20,000 is the VanEck Australian Equal Weight ETF.

This ETF takes a different approach to investing in the Australian market. Instead of weighting companies by size, it gives each holding an equal allocation. This reduces the heavy concentration in large banks and major resource companies that is common in traditional indices.

The result is a more balanced exposure across sectors and companies, without one area dominating the portfolio.

This structure can also create opportunities. In periods of rising interest rates, equal weight strategies have historically outperformed the broader market. There is also greater exposure to companies outside the largest names, which may present opportunities at current valuations.

It was recently recommended by analysts at VanEck.

The post Where to invest $20,000 in ASX ETFs right now appeared first on The Motley Fool Australia.

More reading

• Global X says it’s time to target this electric vehicle ASX ETF that has doubled in a year
• Why this HALO focused ASX ETF outperformed over the last month
• 5 ASX ETFs to buy and hold for five years
• Why I’d buy these BetaShares ETFs for my portfolio in April

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and Tesla. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares are breaking down again on Wednesday, with selling pressure pushing the stock to levels not seen in nearly a decade.

At the time of writing, the CSL share price is down 5.10% to $130.02.

Earlier in afternoon trade, the stock fell as low as $128.675, marking a 9-year low and extending one of the steepest declines seen in a blue-chip behemoth in recent years.

It also comes during a weaker session for the broader market.

The S&P/ASX 200 Index (ASX: XJO) is down 1.07% to 8,853 points, with healthcare among the sectors under pressure.

Here’s what appears to be driving the latest leg lower.

A key demand driver just took a hit

One of the key triggers appears to be fresh policy changes in the United States.

According to The Australian, the US military has scrapped its annual flu shot requirement for service members. While vaccinations remain available, the removal of a broad mandate changes the demand outlook.

CSL generates a significant portion of its revenue from the US, with its influenza vaccines forming part of that exposure.

A policy shift like this feeds directly into investor concerns around vaccine volumes. Lower uptake could weigh on future sales, particularly in segments where demand was previously supported by mandates.

The selling didn’t start today

The latest drop adds to a trend that has been building for some time.

CSL has been working through a slower growth phase, with expectations pulled back over the past 18 months. Earlier updates pointed to softer earnings momentum, driven by pressure in vaccines and margins.

At the same time, healthcare stocks have fallen out of favour in 2026. Capital has moved into other parts of the market, leaving former high-multiple names exposed.

Recent developments across the sector have added to the pressure. Cochlear Ltd (ASX: COH)’s profit warning has weighed on sentiment and reinforced concerns around earnings visibility.

That backdrop has left CSL more vulnerable to negative news.

A blue-chip reset that’s too hard to ignore

The scale of the decline stands out given CSL’s history.

For years, it was viewed as one of the ASX’s most dependable growth companies. Strong earnings expansion and global leadership in plasma therapies supported a premium valuation.

That premium has now been stripped out.

The share price is trading well below prior highs, and valuation multiples have compressed alongside slower growth expectations.

The core business remains solid, particularly in plasma-derived therapies where demand continues to build over time. But the market is placing more weight on near-term earnings than long-term positioning.

Foolish Takeaway

CSL’s slide to a 9-year low reflects a combination of shifting demand expectations and broader sector pressure.

The removal of a US flu shot mandate has added another layer of uncertainty at a time when growth is already under scrutiny.

With sentiment toward healthcare stocks still fragile, the shares have struggled to find support.

The next phase will depend on whether earnings can stabilise and rebuild confidence.

The post CSL’s collapse deepens. Why this ASX giant can’t find a floor appeared first on The Motley Fool Australia.

More reading

• Prediction: CSL shares could surpass $265 in 2026
• Are ASX healthcare shares the next to rally?
• 5 oversold ASX shares to buy before the end of April
• 2 ASX healthcare shares I think can beat the market
• How much could a $10,000 investment in these undervalued ASX 200 shares be worth in a year?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Many of Australia’s top brokers have been busy adjusting their financial models and recommendations again. This has led to a number of broker notes being released this week.

Three ASX shares that brokers have named as buys this week are listed below. Here’s why their analysts are feeling bullish on them right now:

Hub24 Ltd (ASX: HUB)

According to a note out of Bell Potter, its analysts have retained their buy rating on this investment platform provider’s shares with a trimmed price target of $110.00. This follows the release of Hub24’s quarterly update, which revealed net inflows ahead of the broker’s expectations but below consensus estimates. Overall, the broker was pleased and highlights that the quantum of net inflows remains on an upwards trajectory. In addition, the broker points out that Hub24 issued positive language for momentum and highlighted the strong growth in retail net inflows. And while Bell Potter has trimmed its estimates slightly, it still expects earnings per share growth of 33% in FY 2026 and 21% in FY 2027. The Hub24 share price is trading at $86.45 this afternoon.

NextDC Ltd (ASX: NXT)

A note out of Morgan Stanley reveals that its analysts have retained their overweight rating on this data centre operator’s shares with a slightly reduced price target of $18.00. This follows the announcement of a major capital raising to support accelerated construction plans. Morgan Stanley highlights that NextDC has won its largest-ever single contract with a 250MW customer for the S4 data centre in Sydney. While NextDC shares trade at a premium to US peers, the broker believes this is justified given its significantly stronger growth outlook. The NextDC share price is fetching $14.46 at the time of writing.

WiseTech Global Ltd (ASX: WTC)

Another note out of Bell Potter reveals that its analysts have retained their buy rating on this logistics solutions technology company’s shares with a trimmed price target of $78.75. Bell Potter highlights that WiseTech shares are currently trading at a 30% discount to TechnologyOne Ltd (ASX: TNE) on an EV/EBITDA basis in both FY 2026 and FY 2027. And while it believes some sort of discount is now warranted, it thinks the current discount is excessive. This is especially the case given WiseTech has greater forecast earnings growth over the medium term and also a similar strong competitive moat due to 30 years of proprietary data, deeply embedded software and high switching costs. The WiseTech share price is trading at $45.53 on Wednesday.

The post Top brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: ANZ, NAB, and WiseTech shares
• Why are NextDC shares storming higher today?
• NEXTDC completes $1bn institutional entitlement offer to fund growth
• Leading broker says this top ASX 200 share is a buy with 25%+ upside
• Still down 40% over the past year, how high could WiseTech shares recover?

Motley Fool contributor James Mickleboro has positions in Nextdc, Technology One, and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24, Technology One, and WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended Hub24 and Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

A stock doesn’t climb more than 120% in a few months without drawing strong investor attention.

Elsight Ltd (ASX: ELS) has been one of those names in 2026, riding a wave tied to defence and autonomous systems.

The shares are down 5.16% to $6.80 in afternoon trade after the company released its Q1 update.

Even so, the recent run still holds up.

The latest numbers add more detail to what has been building across the business.

Here’s what came through.

Revenue keeps pushing higher

Elsight reported another record quarter, with revenue reaching approximately US$11.6 million.

That marks its 5th consecutive quarter of record revenue and a 12-fold increase compared to the same period last year.

Recurring revenue also continues to build. The company generated US$1.3 million from software licences, cloud services, and connectivity subscriptions, representing 11% of total revenue.

Cash flow remained positive, with net cash from operations of US$3.99 million. Cash on hand rose to US$64 million by the end of March.

There were no material cost overruns or operational issues flagged during the quarter.

Defence contracts and pipeline still expanding

A large part of that growth continues to come from defence.

Elsight delivered units tied to a US$21.2 million contract signed in late 2025 and secured further orders, including a US$460,000 contract from a US public safety customer.

The company is also progressing through the final phase of a US Defence Innovation Unit project, while gaining access to SOCOM’s OTA contracting framework.

The latter opens the door to faster procurement pathways with US defence agencies.

Activity across drone and autonomous programs is also picking up. Engagement is increasing across the US Department of Defense Drone Dominance initiatives, as well as with defence contractors and integrators.

The broader backdrop is helping. Defence budgets are rising globally, with a growing focus on autonomous systems, drones, and secure connectivity in contested environments.

And Elsight’s Halo technology sits directly within that area of demand.

New products and commercial expansion underway

Beyond defence, the company is starting to expand its product offering.

Elsight confirmed the soft launch of its GNSS-denied positioning solution, designed for environments where traditional GPS signals are unreliable.

That represents a step toward becoming a multi-product business, rather than relying on a single connectivity platform.

Its stealth initiative is also moving closer to commercialisation. The business unit has advanced to proof of concept stage, with initial customer engagement already underway.

Management expects first paying customers during CY2026, although early revenue contribution is likely to be modest.

Commercial adoption is also improving, supported by regulatory progress around drone operations and beyond visual line of sight use cases.

Foolish Takeaway

Today’s drop doesn’t change much.

Elsight is still delivering rapid revenue growth, building recurring income, and adding to its contract base.

At the same time, exposure to defence and autonomous systems continues to expand, with more programs moving from testing into real deployment.

After a 120% run, short-term weakness is not unusual.

If contract wins convert into revenue and new products gain traction, the current momentum may still not be fully reflected.

The post Drones, defence, and demand: Why this ASX stock is running hot in 2026 appeared first on The Motley Fool Australia.

More reading

• Why Eden Innovation, Elsight, Paladin Energy, and Zip shares are racing higher today
• Looking for another DroneShield? Check out this buy-rated ASX defence stock
• Up 1,800% in a year, this ASX stock just hit another record high

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

DroneShield Ltd (ASX: DRO) shares are trading slightly lower today following the release of its quarterly results.

That looks more like broader market weakness than anything in the result itself. The S&P/ASX 200 Index (ASX: XJO) is down almost 1% at the time of writing.

Having reviewed the counter-drone technology company’s numbers, I see a few clear takeaways. 

DroneShield’s growth is still accelerating

The first thing that stands out is just how strong the growth remains.

DroneShield reported revenue of $74.1 million for the quarter, which is up 121% on the prior corresponding period and represents its second-highest quarter on record.

What I find interesting here is that this result actually came in ahead of its recent trading update, driven by the timing of deliveries late in March.

To me, that points to demand continuing to build rather than slow down after a strong 2025. The company is still winning work and converting that into revenue at a rapid pace.

Cash flow and balance sheet strength are improving

The second takeaway is how much stronger the financial position looks.

Customer cash receipts hit a record $77.4 million for the quarter, up 360% year on year. At the same time, DroneShield delivered its fourth consecutive quarter of positive operating cash flow.

The company also finished the period with around $222 million in cash and no debt.

I think that combination is important. It gives DroneShield the ability to keep investing in technology, expand its footprint, and potentially pursue acquisitions without needing to raise capital.

The pipeline and recurring revenue opportunity continue to build

The third takeaway is the scale of what sits ahead.

DroneShield has a sales pipeline of around $2.2 billion across more than 300 projects, which provides a clear line of sight into future opportunities.

On top of that, its software and SaaS revenue is growing quickly, up more than 200% in the quarter.

There is also a longer-term goal to lift recurring revenue to 30% of total revenue by 2030, which could make the business more predictable over time.

When I put that together, it suggests the company is not just growing, but also evolving into a more balanced model with a mix of hardware and software revenue.

Foolish Takeaway

Overall, this update highlights strong growth, positive cash flow, and a large sales pipeline that all point to a business that is still moving forward.

That is why I think today’s share price weakness is worth looking past and could be a buying opportunity.

The post 3 key takeaways from DroneShield’s latest results appeared first on The Motley Fool Australia.

More reading

• Why Northern Star, DroneShield and BHP shares are making waves on Wednesday
• DroneShield share price jumps after reporting 121% Q1 revenue increase
• DroneShield delivers record 1Q26 revenue and cash receipts
• $5,000 invested in Droneshield shares 5 years ago is now worth…
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Grace Alvino has positions in DroneShield. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Finding undervalued ASX 200 shares can be a key way to generate impressive investment returns.

The trick is in deciding which shares to invest in.

I’ve had a look at some of the stocks that UBS’ broking house has a buy recommendation on, which might be worth including in your portfolio.

In no particular order, here they are.

Cleanaway Waste Management Ltd (ASX: CWY)

Cleanaway this week hosted an investor day, where it introduced the second phase of its Blueprint 2030 strategy, aimed at generating better returns for shareholders.

The company said it was aiming to expand margins by 260 basis points by optimising its branch network and leveraging the scale of its assets.

It was also looking to accelerate growth through investments in new technology, automation, data, and analytics.

UBS said in its note to clients this week that Cleanaway shares had been weak year to date, “which we see as largely attributable to Cleanaway’s more recent history of inconsistent delivery against cash and earnings expectations, alongside heightened investor caution on Middle East related fuel cost inflation”.

UBS said on the positive side, the company flagged that free cash flow was at an inflection point, “and improvements will be supported by the completion of one-off restructuring costs and catch-up tax, reduced capital intensity (post network investment) and benefits from strategic initiatives”.

UBS has a price target of $3.05 on Cleanaway shares, compared with $2.44 currently.

Lynas Rare Earths Ltd (ASX: LYC)

Lynas reported its quarterly production and sales results this week, and UBS said that, despite a number of positive strategic updates throughout the quarter, the company missed consensus estimates for rare earths production.

UBS said sales revenue of $265 million “disappointed” and led it to downgrade the company’s full-year earnings outlook.

The UBS team added:

Still, we remain positive the thematic and with the view that current operational hurdles will ultimately be overcome and expectation of further earnings growth from heavies and magnets, we remain buy rated.

UBS downgraded its price target for Lynas shares from $23.90 to $23.65, still comfortably higher than the current share price of $19.50.

Challenger Ltd (ASX: CGF)

Challenger also released a third-quarter update this week, in which it revealed that its funds under management had fallen by 10% to $104.5 billion.

Managing Director Nick Hamilton said the company had maintained “strong momentum” though, with sales in annuities performing well.

UBS said the update “revealed continued solid momentum across Life sales including longer-duration/higher margin annuity sales”.

The UBS team said Challenger’s price-to-earnings (P/E) ratio was “undemanding” and “we continue to see compelling value and reiterate our Buy rating”.

UBS increased its price target on Challenger shares by 5 cents to $10.10, compared with the current share price of $8.39.

The post UBS names 3 ASX 200 shares to buy right now appeared first on The Motley Fool Australia.

More reading

• Boom or bust: What’s next for Lynas shares?
• New strategy sparks rebound in this $5bn ASX stock – what’s next?
• Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today
• Why ANZ, Challenger, Hub24, and Lynas shares are dropping today
• Why is everyone talking about Regis Resources, Lynas and Rio Tinto shares on Tuesday?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has recommended Challenger. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Pro Medicus Ltd (ASX: PME) shares are sliding again on Tuesday, adding to a weak start to the year.

The healthcare imaging software stock is down 1.15% to $140.59 in afternoon trade. That leaves it roughly 36% lower in 2026 so far.

That is a significant shift for a stock that has historically traded at a premium. It also raises questions about how the market is now pricing the business.

With attention now turning to whether the sell-off has gone too far, the key question is what happens from here.

A high-quality business, but priced for growth

Pro Medicus operates in a niche corner of healthcare technology, supplying imaging software to hospitals and diagnostic providers.

Its Visage platform allows clinicians to process and interpret medical images quickly, which has helped it build a strong position in large hospital networks, particularly in the United States.

The business model is built around long-term contracts, high margins, and deep integration into hospital systems. Once installed, switching costs are high, which supports recurring revenue and strong visibility over future earnings.

That structure has underpinned years of consistent growth. Its interim results showed revenue and earnings continuing to rise, supported by a growing base of contracted work.

More recently, contract momentum has remained strong. Pro Medicus has secured roughly $100 million in wins and renewals since February, often at higher pricing, with cardiology-related upsell starting to gain traction.

Why the share price has pulled back

The weakness in the share price has been driven more by sentiment than operations.

High-growth healthcare and tech stocks have faced a broad de-rating, and Pro Medicus has not been immune. With a price-to-earnings (P/E) ratio still sitting above 60, the stock remains sensitive to changes in market expectations.

That has been reflected in broker updates.

Morgans recently retained its ‘buy’ rating but reduced its price target to $210. The broker noted it has updated its model to reflect more achievable growth assumptions, staging implementation revenue more conservatively and marking foreign exchange to spot.

Even with those changes, it said the business itself remains strong, and long-term demand is still there.

Bell Potter has taken a similar view. It maintained a positive stance while trimming its target price to $226, still implying material upside from current levels.

What investors are watching now

At current levels, the focus is on delivery.

Pro Medicus continues to win new contracts and expand within existing customers, which is central to its growth outlook. The pace of those wins, and how quickly they convert into revenue, will be closely watched.

At the same time, valuation remains a key factor. Even after the recent fall, the stock still trades at a premium to most of the ASX.

That leaves less room for disappointment if growth slows.

Foolish takeaway

Pro Medicus remains a high-quality business with strong margins and recurring revenue.

The share price fall appears tied more to valuation than any clear change in the business.

And broker support is still there, even with lower price targets.

The recent pullback could be an opportunity for long-term investors if the company continues to grow as expected.

The post Are Pro Medicus shares a buy right now? appeared first on The Motley Fool Australia.

More reading

• Are ASX healthcare shares the next to rally?
• Buy, hold, sell: Collins Foods, Netwealth, and Pro Medicus shares
• Want to double your money in 2026? This is what I’d buy
• Leading brokers name 3 ASX shares to buy today
• How much could a $10,000 investment in these undervalued ASX 200 shares be worth in a year?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares are tumbling again today as investors continue selling up their interest in the Australian biotech company.

At the time of writing, the shares are down 4.6% to $130.70 a piece.

Today’s decline means the shares are now down 24% for the year to date and 45% lower than a year ago.

Analysts have widely considered the biotech company’s shares oversold and undervalued for some time now, and they’re tipping a significant upside ahead.

TradingView data shows that 12 out of 18 analysts have a buy or strong buy rating on the shares. Another six have a hold rating.

The average target price is $200.35, which implies a potential 53% upside at the time of writing. 

But others are even more bullish and expect the shares could jump 104% to $267.79 in the next 12 months.  

Here’s why CSL shares could surpass $265

There are a few reasons why CSL shares are tipped to fly higher this year. From easing headwinds to robust demand, CSL could write a great growth story in 2026.

CSL has posted some uninspiring financial results over the past 18 months. It also heavily downgraded its FY26 revenue and growth profit guidance in late 2025. The biotech giant lowered its FY26 NPATA growth forecast to 4% to 7% (down from 7% to 10% previously), citing falling US vaccine demand and pricing pressures.

The company has announced a surprise restructure and a shock CEO exit over the past year, spooking investors and sending the company’s share price south. 

But it looks like many of these headwinds are now easing, and the downward pressure on CSL shares could quickly rebound.

At the core of CSL’s business is its plasma-derived medicine division. This includes immunoglobulins, albumin, and clotting factors. 

The company’s blood plasma division dominates the market for rare blood disorders and immunoglobulin products. 

Global demand for plasma therapies is strong and growing, too. There is recurring demand and limited competition, which makes CSL well-placed to carve out a significant portion of the market.

Recent reports indicate that the blood plasma derivatives market was valued at $52.16 billion in 2025. By 2033, it is expected to explode to $104.30 billion.

Not only is demand for its productions booming, CSL is also entering a key investment phase, which could help boost its financials. I’d expect investor confidence will follow suit.

Why hasn’t CSL already started gaining momentum?

It’s a good question, and one that is two-fold.

CSL was once widely viewed as one of the most dependable growth companies on the ASX. But over the past few years, it has experienced a notable slowdown in earnings growth, and investors have lost confidence in its pipeline and expansion plans.

At the same time, the Australian sharemarket has seen a broad market rotation away from healthcare-related stocks in 2026, in favour of defensive assets.

Ultimately, it looks like CSL’s growth trajectory is on the right path. And as soon as investors regain some confidence and jump on board, the share price could quickly be on its way to surpass the $265 mark in 2026.

The post Prediction: CSL shares could surpass $265 in 2026 appeared first on The Motley Fool Australia.

More reading

• Are ASX healthcare shares the next to rally?
• 5 oversold ASX shares to buy before the end of April
• 2 ASX healthcare shares I think can beat the market
• How much could a $10,000 investment in these undervalued ASX 200 shares be worth in a year?
• How to build a Warren Buffett-inspired ASX share portfolio

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.